MedPage Today November 11, 2024
Sentynl Therapeutics, Inc.

About Dr. Wendy Chung and the GUARDIAN Study

Hello, I’m Dr. Liza Squires, a Medical Consultant at Sentynl Therapeutics, a U.S.-based biopharmaceutical company focused on rare disease.

Today, I’m here with Dr. Wendy Chung, a clinical and molecular geneticist and Chief of the Department of Pediatrics at Boston Children’s Hospital and Harvard Medical School. Today, we’ll discuss the importance of advancing newborn screening with whole genome sequencing, and how healthcare providers can advocate for this important advancement.

Dr. Chung, thank you for your time. Could you share a bit about your background and work in newborn screening and genetics?

Dr. Chung

Thanks Liza, it’s good to be here. For the past 35 years, I’ve dedicated my career to genetics and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Pharma / Biotech, Precision Medicine, Survey / Study, Trends
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
Exploring Precision Medicine and PGx: Sara Rogers, PharmD, Previews Precision Medicine World Conference 2025
India targets to sequence 10 million genomes
23andMe considers sale as cash runs low
23andMe considers a sale as cash runs low

Share This Article